



Ophthalmic business sold to



Merodis

Advisor to Seller

Merodis advises Laboratoire Gifrer on the carve-out of its Ophthalmic business

24 July 2019, Brussels, Belgium.

Merodis (www.merodis.com), an independent corporate finance advisory firm, is pleased to announce that it successfully advised **Laboratoire Gifrer Barbezat** in the carve-out of its ophthalmic business to the **Laboratoire SIFI**, a leading Italian company in that field.

Gifrer's ophthalmic business consists of a market leading drug, **Dacudoses®**, and the collyrium brand **Novoptine®**, with a total turnover of c. EUR 6 million. Dacudoses is the leading reimbursed brand of the French ophthalmic antiseptic market segment, prescribed by ophthalmologists and general practitioners. Dacudoses is commonly used as an eyewash in case of light conjunctivitis and/or infections, benefitting from a very strong brand recognition in France. Novoptine is an over-the-counter antiseptic collyrium used to treat eye infections and conjunctivitis.

Laboratoire Gifrer Barbezat is a leading French pharmaceutical company providing households with authentic, natural, safe and efficient drugs to treat daily benign pathologies. The company was acquired in 2001 by the Verlinden family who also owns **Qualiphar**, a leading Belgian pharmaceutical group. Gifrer's decision to sell its valuable ophthalmic assets was driven by its recent strategic decision to focus on maternal and child healthcare products.

With this acquisition, **SIFI** is pursuing its international expansion strategy, with the aim of becoming a key independent player in ophthalmology, leveraging on its know-how, expertise and unique assets. Both products will be marketed through its subsidiary **SIFI France**, as from January 2020.

For more information,
please contact:

Dirk Marckx
dma@merodis.com
+32 495 38 17 81

Rodolphe Blondiau
rbl@merodis.com
+32 488 81 45 07

William Assenmacher
was@merodis.com
+32 474 34 28 19

Merodis
Financial Services